Greenstein Leonard M.
Known title: CFO, TreasurerCIK: 0001519692
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals. The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.
Transaction History
| CARL | ▲ Buy | Grant | 44,977 | $0 | 1/28/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 5,000 | $70K | 4/20/2023 | View on chart |
| TARS | ▼ Sell | Open Market | 346 | $4K | 3/23/2023 | View on chart |
| TARS | ▼ Sell | Open Market | 332 | $4K | 3/22/2023 | View on chart |
| TARS | ▼ Sell | Open Market | 326 | $4K | 3/21/2023 | View on chart |
| TARS | ▼ Sell | Open Market | 333 | $4K | 3/20/2023 | View on chart |
| TARS | ▼ Sell | Open Market | 316 | $4K | 3/17/2023 | View on chart |
| TARS | ▼ Sell | Open Market | 313 | $4K | 3/16/2023 | View on chart |
| TARS | ▼ Sell | Open Market | 5,000 | $67K | 3/16/2023 | View on chart |
| TARS | ▲ Buy | Option Exercise | 4,462 | — | 3/15/2023 | View on chart |
| TARS | ▼ Sell | Open Market | 5,000 | $76K | 2/16/2023 | View on chart |
| TARS | ▼ Sell | Open Market | 5,000 | $73K | 1/19/2023 | View on chart |
| TARS | ▼ Sell | Open Market | 5,000 | $73K | 12/15/2022 | View on chart |
| TARS | ▼ Sell | Open Market | 5,000 | $83K | 11/17/2022 | View on chart |
| TARS | ▼ Sell | Open Market | 4,877 | $78K | 10/20/2022 | View on chart |
| TARS | ▼ Sell | Open Market | 123 | $2K | 10/20/2022 | View on chart |
| TARS | ▼ Sell | Open Market | 5,000 | $80K | 9/15/2022 | View on chart |
| TARS | ▼ Sell | Open Market | 5,000 | $82K | 8/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
CARL CFO Appointment and FY2026 Revenue Guidance Confirmed
Carlsmed announced Richard Heppenstall as its new chief financial officer, succeeding Leo Greenstein. The company also reaffirmed its FY2026 sales guidance of $74 million to $78 million, matching analyst estimates. BTIG kept its price target at $23 following the announcements.
CARL CFO Appointment and FY2026 Revenue Guidance Confirmed. Carlsmed announced Richard Heppenstall as its new chief financial officer, succeeding Leo Greenstein. The company also reaffirmed its FY2026 sales guidance of $74 million to $78 million, matching analyst estimates. BTIG kept its price target at $23 following the announcements.